Yes, several clinical trials are evaluating the efficacy of CAF inhibitors in various types of cancer. For example, clinical trials involving drugs that target the TGF-β pathway are ongoing in patients with pancreatic and breast cancer. These trials aim to assess the safety and effectiveness of CAF inhibitors in combination with standard treatments like chemotherapy and immunotherapy.
